Observational studyThe journal of obstetrics and gynaecology research2026
Safety of Ferric Citrate Hydrate in Pregnant Women With Iron Deficiency Anemia, Fetuses, and Newborns: A Real-World, Observational, Post-Marketing Surveillance Study.
Observational study in The journal of obstetrics and gynaecology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimThis post-marketing surveillance study determined the real-world use and safety of ferric citrate hydrate (FC) in fetuses and pregnant women with iron deficiency anemia (IDA).
methodsPregnant women with IDA were registered centrally and followed prospectively from the first FC administration until the end of pregnancy or at treatment discontinuation. Demographic characteristics, FC administration, and levels of iron- and anemia-related parameters were collected. Newborns were followed for 7 days after birth.
resultsRegistration was from October 2021 to March 2023, and 149 women and 129 newborns were included for analysis. The mean (standard deviation; SD) age of the women was 32.1 (5.1) years, and 75.8% were at ≥ 28 weeks of gestational age at the first FC administration. The mean (SD) daily dose of FC was 494.2 (36.3) mg. FC treatment was continued until the end of pregnancy in 53 of 149 women (35.6%). The most frequent reason for the discontinuation of FC (96/149 women, 64.4%) was an improvement in IDA (68/149 women, 45.6%). Adverse drug reactions (ADRs) led to discontinuation in 4 of 149 women (2.7%). In 7 of 149 women (4.7%), 9 ADRs were found, including constipation (3/149, 2.0%), nausea (2/149, 1.3%), abdominal pain upper (1/149, 0.7%), diarrhea (1/149, 0.7%), hand dermatitis (1/149, 0.7%), and fetal death (1/149, 0.7%). No ADRs were found in newborns. Hemoglobin and serum ferritin levels were increased with FC treatment, but no signs of iron overload were reported.
conclusionsNo previously unknown safety concerns were detected in women, fetuses, or newborns by FC treatment during pregnancy.
trial registrationjRCT2031210322.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.